Literature DB >> 6460588

Moxalactam epimer kinetics in children.

M C Nahata, D E Durrell, W J Barson.   

Abstract

The kinetics of the R and S epimers of moxalactam were followed after single intravenous doses of 50 mg/kg to 12 patients, 8 to 45 mo old, with cellulitis or epiglottitis. High-pressure liquid chromatography was used to determine serum concentrations. Total body clearance and apparent volume of distribution of the R epimer were higher than those of the S epimer (P less than 0.004). Total body clearance of R, S, and R + S moxalactam ranged from 29.01 to 183.7, 19.00 to 79.95, and 23.34 to 113.6 ml/min/m2. Mean elimination half-lives of R, S, and R + X moxalactam were 2.04, 2.26, and 2.24 hr. The higher incidence of the more active R epimer and the 500% interpatient variation in clearance may indicate a need for monitoring serum and cerebrospinal fluid concentrations in patients with severe unresponsive central nervous system infectious treated with moxalactam.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460588     DOI: 10.1038/clpt.1982.71

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

2.  Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children.

Authors:  Yang Wang; Dan Sun; Yan Mei; Sanlan Wu; Xinlin Li; Sichan Li; Jun Wang; Liuliu Gao; Hua Xu; Yali Tuo
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

3.  Human pharmacokinetics and antimicrobial activities of the temocillin epimers.

Authors:  E A Guest; R Horton; G Mellows; B Slocombe; A J Swaisland; T C Tasker; A R White
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 5.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.